CDC/ACIP [to 8 Dec 2018]

CDC/ACIP [to 8 Dec 2018]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

MMWR News Synopsis for Friday, December 7, 2018
Public Health Response to an Avian Influenza H7N8 Outbreak in Commercial Turkey Flocks— Indiana, 2016
Surveillance for influenza among responders to an outbreak of avian influenza in turkeys in Indiana in 2016 did not detect any human illnesses. Highly pathogenic avian influenza outbreaks are animal health emergencies that require aggressive control measures. If the virus causing an outbreak is capable of causing human illness, then there could be health risks for the responders. The Indiana State Department of Health and the Dubois County Health Department worked together to monitor the health of people who responded to an outbreak of avian influenza in commercial turkey flocks in 2016. No human cases of avian influenza were detected.

Announcements
 
 
BMGF – Gates Foundation  [to 8 Dec 2018]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.
 
 
Bill & Melinda Gates Medical Research Institute    [to 8 Dec 2018]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
 
 
CARB-X   [to 8 Dec 2018]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
 
 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 8 Dec 2018]
http://cepi.net/
Press releases
Canadian PM, Justin Trudeau, reaffirms commitment to CEPI at the G20
Posted on 02ND DEC 2018 by Mario Christodoulou
In support of the G20 efforts on global health, Canadian Prime Minister, Justin Trudeau, announced an additional CAD10 million contribution to the Coalition for Epidemic Preparedness Innovations (CEPI), which will help us develop new life-saving vaccines to combat emerging infectious diseases…
 
 
EDCTP    [to 8 Dec 2018]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.
 
 
Emory Vaccine Center    [to 8 Dec 2018]
http://www.vaccines.emory.edu/
No new digest content identified.
 
 
European Medicines Agency  [to 8 Dec 2018]
http://www.ema.europa.eu/ema/
News and press releases
No new digest content identified.
 
 
European Vaccine Initiative  [to 8 Dec 2018]
http://www.euvaccine.eu/news-events
05 December 2018
TDR Clinical Research & Development Fellowships
Deadline for submission: 7 March 2019, 16:00 (GMT)
 
 
FDA [to 8 Dec 2018]
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
No new digest content identified.
 
 
December 06, 2018 –
Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s new strategic framework to advance use of real-world evidence to support development of drugs and biologics
December 04, 2018 –
FDA takes new action to advance the development of reliable and beneficial genetic tests that can improve patient care

 
Fondation Merieux  [to 8 Dec 2018]
http://www.fondation-merieux.org/
Partner event
ASLM 2018 – Preventing and controlling the next pandemic: the role of laboratory
December 10 – 13, 2018 – Abuja (Nigeria)
 
 
Mérieux Foundation co-organized event
Dengue pre-vaccination screening based on serostatus: rapid tests and implementation strategies
January 14 – 16, 2019 – Les Pensières Center for Global Helath, Veyrier du Lac (France)
 
 
Gavi [to 8 Dec 2018]
https://www.gavi.org/
05 December 2018
Harnessing the power of partnerships to benefit maternal, newborn & child health
The Partners Forum for The Partnership for Maternal, Newborn & Child Health represents a landmark opportunity to push for action to improve the health and well-being of women, children and adolescents
New Delhi, India, 5 December – Gavi’s Deputy CEO, Anuradha Gupta, will join over 1,200 representatives from governments, civil society and the private sector at a high-level meeting in New Delhi (12–13 December) to demonstrate the power of partnerships to improve and transform the lives of women, children and adolescents.
Hosted by the Government of India, the Partners’ Forum of The Partnership for Maternal, Newborn & Child Health (PMNCH) will set out to align objectives, strategies and resources, as well as seeking agreement on interventions to improve maternal, newborn, child and adolescent health…
 
 
Mobile phones and digital technology to boost vaccine delivery in Uganda
New collaboration will address vaccine supply challenges in 171 health facilities ensuring that children in the hardest-to-reach areas are protected with vaccines.
Geneva, 4 December 2018 – Thousands of children living in the densely populated districts of Wakiso, Nakaseke and Nakasongola in central Uganda will get better access to life-saving vaccines thanks to a new collaboration between the Uganda Ministry of Health, Gavi, the Vaccine Alliance, UPS and Freight in Time Ltd (FIT). The 18 month pilot project will use a customised mobile app and a wireless temperature monitoring system to help address supply chain challenges in 171 health facilities in three districts with the some of the lowest immunisation coverage and the highest number of unimmunised children in the country…
 
 
GHIT Fund   [to 8 Dec 2018]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.
 
 
Global Fund  [to 8 Dec 2018]
https://www.theglobalfund.org/en/news/
02 December 2018
At Mandela 100, Global Fund Builds on South Africa’s Progress against HIV
The Global Fund to Fight AIDS, Tuberculosis and Malaria strengthened its partnership with South Africa in the fight against HIV, announcing a new grant aimed at capitalizing on strong HIV programs to make even greater progress in treatment and prevention, in protecting and promoting human rights, and in strengthening health systems.
The grant, for US$369 million, includes specific efforts aimed at lowering HIV infection rates among adolescent girls and young women who are disproportionately affected by the disease…
 
 
Hilleman Laboratories   [to 8 Dec 2018]
http://www.hillemanlabs.org/
No new digest content identified.
 
 
Human Vaccines Project   [to 8 Dec 2018]
http://www.humanvaccinesproject.org/media/press-releases/
No new digest content identified.
 
 
IAVI  [to 8 Dec 2018]
https://www.iavi.org/newsroom
No new digest content identified.
 
 
IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.
 
 
IVAC  [to 8 Dec 2018]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
No new digest content identified.
 
 
IVI   [to 8 Dec 2018]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.
 
 
JEE Alliance  [to 8 Dec 2018]
https://www.jeealliance.org/
No new digest content identified.
 
 
MSF/Médecins Sans Frontières  [to 8 Dec 2018]
http://www.msf.org/
Selected News; Project Updates, Reports
Pakistan
Bringing hope to sufferers of a neglected disease
Project Update 5 Dec 2018
In May, MSF opened a treatment centre for cutaneous leishmaniasis  in Peshawar – its fourth in Pakistan.

 

Hepatitis C
Appeal lodged against decision to uphold Gilead’s patent on hepatitis C drug
Press Release 5 Dec 2018
Paris – Six organisations, including Médecins Sans Frontières (MSF), have just appealed the European Patent Office’s September decision to uphold US pharmaceutical corporation Gilead Science’s patent on the key hepatitis C drug sofosbuvir.
The appeal – filed by Médecins du Monde (MdM), MSF, AIDES (France), Access to Medicines Ireland, Praksis (Greece) and Salud por Derecho (Spain) – states that the European Patent Office (EPO) should revoke Gilead’s patent because it does not meet the requirements to be a patentable invention from a legal or scientific perspective.
 
 
Democratic Republic of Congo
Ebola spreads further into urban communities and isolated areas in North Kivu
Project Update 3 Dec 2018
The Ebola epidemic continues to spread through the Democratic Republic of Congo (DRC)’s North Kivu province. The newest areas to be affected include the city of Butembo and a number of isolated areas that are hard to reach. So far, 440 people have been infected with the virus, 255 of whom have died. Our teams continue to strengthen their efforts to help bring the epidemic under control.
 
 
NIH  [to 8 Dec 2018]
http://www.nih.gov/news-events/news-releases
December 4, 2018
NIH researcher presents encouraging results for gene therapy for severe sickle cell disease
— This study is part of decades of research on sickle cell disease that have opened the door to novel genetic approaches to curative therapies.
A scientist from the National Institutes of Health will present promising, early results from a human clinical trial testing a novel gene replacement therapy in people with severe sickle cell disease. Preliminary findings suggest that the approach has an acceptable level of safety and might help patients consistently produce normal red blood cells instead of the sickle-shaped ones that mark this painful, life-threatening disease.
The experimental treatment involves removing hematopoietic stem cells from the patients’ bone marrow or blood and adding a therapeutic beta globin gene, which is defective in people with sickle cell disease. The cells are then returned to the patients, leading to the production of anti-sickling hemoglobin (T87Q).
Current data from the ongoing HGB-206 Phase 1 multicenter nationwide study will be presented at the 60th Annual Meeting of the American Society of Hematology (ASH), Dec. 1-4, in San Diego…
 
 
PATH  [to 8 Dec 2018]
https://www.path.org/media-center/
No new digest content identified.
 
 
Sabin Vaccine Institute  [to 8 Dec 2018]
http://www.sabin.org/updates/pressreleases
No new digest content identified.
 
 
UNAIDS [to 8 Dec 2018]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
4 December 2018
South Africa launches campaign to expand access to HIV treatment
On World AIDS Day, South Africa launched a multidisease national wellness campaign to accelerate screening and testing for HIV, tuberculosis, sexually transmitted infections and noncommunicable diseases, including hypertension and diabetes. The campaign, known as Cheka Impilo, is a direct response to the call by the President of South Africa, Cyril Ramaphosa, during his first State of the Nation address in February 2018 to initiate an additional 2 million people on HIV treatment by 2020, find 88 000 missing tuberculosis cases annually and screen 7 million people for noncommunicable diseases in the first year…
 
 
UNICEF  [to 8 Dec 2018]
https://www.unicef.org/media/press-releases
Selected Press Releases/Reports/Statements
Statement
Humanitarian assistance continues to prevent a massive human catastrophe in Yemen but it is not enough
UN agencies warn that an urgent scale up of humanitarian assistance is needed to save lives
07/12/2018
 
 
Press release
Refugee and migrant children and youth report severe deprivations while on the move – UNICEF
UNICEF releases alarming data from poll of nearly 4,000 refugee and migrant children and youth ahead of Global Compact for Migration Summit in Marrakech
07/12/2018
 
 
Vaccine Confidence Project  [to 8 Dec 2018]
http://www.vaccineconfidence.org/
No new digest content identified.
 
 
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 8 Dec 2018]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.
 
 
Wellcome Trust  [to 8 Dec 2018]
https://wellcome.ac.uk/news
Opinion | 6 December 2018
Social science research: a much-needed tool for epidemic control
João Rangel de Almeida
Portfolio Development Manager Wellcome
To control epidemics, it’s essential to understand the contexts where they take place. Social researchers are helping to uncover ethical and practical challenges that are critical to the people caught in the middle of an outbreak.
 
 
Explainer | 5 December 2018
Research saves lives in epidemics like Ebola
Protecting the people of the Democratic Republic of the Congo from Ebola takes a chain of responders from all over the world. With one outbreak earlier this year over, and a second ongoing, research has been at the heart of the response.
 
 
Q&A | 4 December 2018
What are human infection studies and why do we need them?
Human infection studies have the power to rapidly accelerate the development of much-needed vaccines and treatments. In this Q&A, we explain what they are, how they work and why they are important.
 
 
News | 3 December 2018
Second global call to action against drug-resistant infections
Wellcome has co-hosted a second global event, in Ghana, to help drive pioneering action to stop the rise and spread of superbugs.
 
 
The Wistar Institute   [to 8 Dec 2018]
https://www.wistar.org/news/press-releases
No new digest content identified.
 
 
World Organisation for Animal Health (OIE)   [to 8 Dec 2018]
http://www.oie.int/en/for-the-media/press-releases/2018/
No new digest content identified. 

::::::

 
BIO    [to 8 Dec 2018]
https://www.bio.org/insights/press-release
No new digest content identified.
 
 
DCVMN – Developing Country Vaccine Manufacturers Network  [to 8 Dec 2018]
http://www.dcvmn.org/
No new digest content identified.
 
 
IFPMA   [to 8 Dec 2018]
http://www.ifpma.org/resources/news-releases/
05 December 2018
R&D biopharmaceutical industry revamp ethical code to apply as base line of industry behavior worldwide
: New R&D biopharmaceutical industry Code of Practice comes into effect on 1 January 2019.
:: Changes reflect increasingly complex dilemmas faced by R&D biopharmaceutical industry professionals which call just as much for rules, as for strong ethical values that can build a culture of trust.
:: New Code of Practice aims to improve guidance to IFPMA members on how to conduct business when interacting with the healthcare community worldwide.

04 December 2018
David A. Ricks Elected New President of the International Federation of Pharmaceutical Manufacturers & Associations
:: David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly and Company, takes over as President of IFPMA from Ian C. Read, Chairman of the Board and Chief Executive Officer, Pfizer.
:: New President to highlight the need for forward-looking policies that encourage innovation, as well as strengthened health systems in order to sustain the last-half century’s hard-won global health gains.
:: The outgoing President leaves a legacy of biopharmaceutical collaborative firsts: Access Accelerated, Pat-INFORMED and AMR Industry Alliance.
 
 
PhRMA    [to 8 Dec 2018]
http://www.phrma.org/press-room
No new digest content identified.

 

Journal Watch

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Do Incarcerated Populations Serve as a Reservoir for Tuberculosis in South Africa?

American Journal of Tropical Medicine and Hygiene
Volume 99, Issue 6, 2018
http://www.ajtmh.org/content/journals/14761645/99/6

Articles
Do Incarcerated Populations Serve as a Reservoir for Tuberculosis in South Africa?
Alana Sharp, J. Travis Donahoe, Amanda Milliken, Jacqueline Barocio, Salome Charalambous and Zoë M. McLaren
https://doi.org/10.4269/ajtmh.17-0652

 

 

Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial

Annals of Internal Medicine
4 December 2018 Vol: 169, Issue 11
http://annals.org/aim/issue

Original Research
Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial
Anna H.E. Roukens, MD, PhD *; Karlijn van Halem, MD *; Adriëtte W. de Visser, BSc; Leo G. Visser, MD, PhD
Abstract
Background:
Outbreaks of yellow fever and a frequently depleted vaccine stock increase demand for a dose-sparing strategy. A fractional dose of 17D yellow fever virus (17D-YFV) vaccine has been shown to be noninferior to the standard dose in inducing seroprotection.
Objective:
To evaluate whether fractional-dose vaccination can confer long-term immunity.
Design:
10-year follow-up of a subgroup of a randomized, controlled, noninferiority trial. (Dutch Trial Register: NTR7094 [current study] and ISRCTN46326316 [original study])
Setting:
The Netherlands.
Participants:
Seventy-five of 155 participants in the original trial provided a blood sample for this study. These 75 participants had received primary vaccination with 17D-YFV vaccine 10 years before. Forty received a 0.1-mL fractional dose intradermally, and 35 received the standard 0.5-mL dose subcutaneously.
Measurements:
Virus-neutralizing antibody responses were measured by a plaque reduction neutralization test.
Results:
Thirty-nine of 40 (98% [95% CI, 89% to 100%]) participants had protective levels of yellow fever–neutralizing antibodies more than 10 years after receiving a fractional dose of 17D-YFV vaccine compared with 34 of 35 (97% [CI, 87% to 100%]) in the standard-dose group.
Limitation:
Only 48% of participants from the original trial participated in this study.
Conclusion:
Intradermal administration of a one-fifth dose of yellow fever vaccine induced a protective immune response that lasted for 10 years after vaccination. Persons receiving a fractional dose of yellow fever vaccine do not require a booster vaccination for long-term protection against yellow fever.
Primary Funding Source:
Leiden University Medical Center and the International Society of Travel Medicine.